673 related articles for article (PubMed ID: 31707805)
1. Novel Oral Anticoagulant Based Versus Vitamin K Antagonist Based Double Therapy Among Stented Patients With Atrial Fibrillation: Insights From the PIONEER AF-PCI Trial.
Kerneis M; Yee MK; Mehran R; Nafee T; Bode C; Halperin JL; Peterson ED; Verheugt FWA; Wildgoose P; van Eickels M; Lip GYH; Cohen M; Fox KAA; Gibson CM
Circ Cardiovasc Interv; 2019 Nov; 12(11):e008160. PubMed ID: 31707805
[TBL] [Abstract][Full Text] [Related]
2. Association of International Normalized Ratio Stability and Bleeding Outcomes Among Atrial Fibrillation Patients Undergoing Percutaneous Coronary Intervention.
Kerneis M; Yee MK; Mehran R; Nafee T; Bode C; Halperin JL; Peterson ED; Verheugt FWA; Wildgoose P; van Eickels M; Lip GYH; Cohen M; Fox KAA; Gibson CM
Circ Cardiovasc Interv; 2019 Feb; 12(2):e007124. PubMed ID: 30704287
[TBL] [Abstract][Full Text] [Related]
3. Effect of Procedure and Coronary Lesion Characteristics on Clinical Outcomes Among Atrial Fibrillation Patients Undergoing Percutaneous Coronary Intervention: Insights From the PIONEER AF-PCI Trial.
Kerneis M; Gibson CM; Chi G; Mehran R; AlKhalfan F; Talib U; Pahlavani S; Mir M; Bode C; Halperin JL; Nafee T; Peterson ED; Verheugt FWA; Wildgoose P; van Eickels M; Lip GYH; Fox KAA; Cohen M
JACC Cardiovasc Interv; 2018 Apr; 11(7):626-634. PubMed ID: 29550085
[TBL] [Abstract][Full Text] [Related]
4. Total bleeding with rivaroxaban versus warfarin in patients with atrial fibrillation receiving antiplatelet therapy after percutaneous coronary intervention.
Chi G; Yee MK; Kalayci A; Kerneis M; AlKhalfan F; Mehran R; Bode C; Halperin JL; Verheugt FWA; Wildgoose P; van Eickels M; Lip GYH; Cohen M; Peterson ED; Fox KAA; Gibson CM
J Thromb Thrombolysis; 2018 Oct; 46(3):346-350. PubMed ID: 29943350
[TBL] [Abstract][Full Text] [Related]
5. Recurrent Hospitalization Among Patients With Atrial Fibrillation Undergoing Intracoronary Stenting Treated With 2 Treatment Strategies of Rivaroxaban or a Dose-Adjusted Oral Vitamin K Antagonist Treatment Strategy.
Gibson CM; Pinto DS; Chi G; Arbetter D; Yee M; Mehran R; Bode C; Halperin J; Verheugt FW; Wildgoose P; Burton P; van Eickels M; Korjian S; Daaboul Y; Jain P; Lip GY; Cohen M; Peterson ED; Fox KA
Circulation; 2017 Jan; 135(4):323-333. PubMed ID: 27881555
[TBL] [Abstract][Full Text] [Related]
6. An open-label, randomized, controlled, multicenter study exploring two treatment strategies of rivaroxaban and a dose-adjusted oral vitamin K antagonist treatment strategy in subjects with atrial fibrillation who undergo percutaneous coronary intervention (PIONEER AF-PCI).
Gibson CM; Mehran R; Bode C; Halperin J; Verheugt F; Wildgoose P; van Eickels M; Lip GY; Cohen M; Husted S; Peterson E; Fox K
Am Heart J; 2015 Apr; 169(4):472-8.e5. PubMed ID: 25819853
[TBL] [Abstract][Full Text] [Related]
7. Use of Dual Antiplatelet Therapy and Patient Outcomes in Those Undergoing Percutaneous Coronary Intervention: The ROCKET AF Trial.
Sherwood MW; Cyr DD; Jones WS; Becker RC; Berkowitz SD; Washam JB; Breithardt G; Fox KA; Halperin JL; Hankey GJ; Singer DE; Piccini JP; Nessel CC; Mahaffey KW; Patel MR
JACC Cardiovasc Interv; 2016 Aug; 9(16):1694-702. PubMed ID: 27539689
[TBL] [Abstract][Full Text] [Related]
8. Prevention of Bleeding in Patients with Atrial Fibrillation Undergoing PCI.
Gibson CM; Mehran R; Bode C; Halperin J; Verheugt FW; Wildgoose P; Birmingham M; Ianus J; Burton P; van Eickels M; Korjian S; Daaboul Y; Lip GY; Cohen M; Husted S; Peterson ED; Fox KA
N Engl J Med; 2016 Dec; 375(25):2423-2434. PubMed ID: 27959713
[TBL] [Abstract][Full Text] [Related]
9. Risk/Benefit Tradeoff of Antithrombotic Therapy in Patients With Atrial Fibrillation Early and Late After an Acute Coronary Syndrome or Percutaneous Coronary Intervention: Insights From AUGUSTUS.
Alexander JH; Wojdyla D; Vora AN; Thomas L; Granger CB; Goodman SG; Aronson R; Windecker S; Mehran R; Lopes RD
Circulation; 2020 May; 141(20):1618-1627. PubMed ID: 32223444
[TBL] [Abstract][Full Text] [Related]
10. Concomitant Use of Single Antiplatelet Therapy With Edoxaban or Warfarin in Patients With Atrial Fibrillation: Analysis From the ENGAGE AF-TIMI48 Trial.
Xu H; Ruff CT; Giugliano RP; Murphy SA; Nordio F; Patel I; Shi M; Mercuri M; Antman EM; Braunwald E
J Am Heart Assoc; 2016 Feb; 5(2):. PubMed ID: 26908401
[TBL] [Abstract][Full Text] [Related]
11. Combining Oral Anticoagulants With Platelet Inhibitors in Patients With Atrial Fibrillation and Coronary Disease.
Sindet-Pedersen C; Lamberts M; Staerk L; Nissen Bonde A; Berger JS; Pallisgaard JL; Lock Hansen M; Torp-Pedersen C; Gislason GH; Olesen JB
J Am Coll Cardiol; 2018 Oct; 72(15):1790-1800. PubMed ID: 30286922
[TBL] [Abstract][Full Text] [Related]
12. Switching of Oral Anticoagulation Therapy After PCI in Patients With Atrial Fibrillation: The RE-DUAL PCI Trial Subanalysis.
Ten Berg JM; de Veer A; Oldgren J; Steg PG; Zateyshchikov DA; Jansky P; Seung KB; Hohnloser SH; Lip GYH; Nordaby M; Kleine E; Bhatt DL; Cannon CP;
JACC Cardiovasc Interv; 2019 Dec; 12(23):2331-2341. PubMed ID: 31806214
[TBL] [Abstract][Full Text] [Related]
13. Effect of Lesion Complexity and Clinical Risk Factors on the Efficacy and Safety of Dabigatran Dual Therapy Versus Warfarin Triple Therapy in Atrial Fibrillation After Percutaneous Coronary Intervention: A Subgroup Analysis From the REDUAL PCI Trial.
Berry NC; Mauri L; Steg PG; Bhatt DL; Hohnloser SH; Nordaby M; Miede C; Kimura T; Lip GYH; Oldgren J; Ten Berg JM; Cannon CP
Circ Cardiovasc Interv; 2020 Apr; 13(4):e008349. PubMed ID: 32252548
[TBL] [Abstract][Full Text] [Related]
14. Efficacy and safety of rivaroxaban compared with warfarin among elderly patients with nonvalvular atrial fibrillation in the Rivaroxaban Once Daily, Oral, Direct Factor Xa Inhibition Compared With Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation (ROCKET AF).
Halperin JL; Hankey GJ; Wojdyla DM; Piccini JP; Lokhnygina Y; Patel MR; Breithardt G; Singer DE; Becker RC; Hacke W; Paolini JF; Nessel CC; Mahaffey KW; Califf RM; Fox KA;
Circulation; 2014 Jul; 130(2):138-46. PubMed ID: 24895454
[TBL] [Abstract][Full Text] [Related]
15. Safety and efficacy of non-vitamin K oral anticoagulant for atrial fibrillation patients after percutaneous coronary intervention: A bivariate analysis of the PIONEER AF-PCI and RE-DUAL PCI trial.
Chi G; Kerneis M; Kalayci A; Liu Y; Mehran R; Bode C; Halperin JL; Verheugt FWA; Wildgoose P; van Eickels M; Lip GYH; Cohen M; Peterson ED; Fox KAA; Gibson CM
Am Heart J; 2018 Sep; 203():17-24. PubMed ID: 30015064
[TBL] [Abstract][Full Text] [Related]
16. Antiplatelet therapy for stable coronary artery disease in atrial fibrillation patients taking an oral anticoagulant: a nationwide cohort study.
Lamberts M; Gislason GH; Lip GY; Lassen JF; Olesen JB; Mikkelsen AP; Sørensen R; Køber L; Torp-Pedersen C; Hansen ML
Circulation; 2014 Apr; 129(15):1577-85. PubMed ID: 24470482
[TBL] [Abstract][Full Text] [Related]
17. Antithrombotic therapy in patients with atrial fibrillation undergoing coronary artery stenting.
Lacoste JL; Hansen CL
Am J Health Syst Pharm; 2019 Sep; 76(18):1395-1402. PubMed ID: 31505555
[TBL] [Abstract][Full Text] [Related]
18. Comparison of the short-term risk of bleeding and arterial thromboembolic events in nonvalvular atrial fibrillation patients newly treated with dabigatran or rivaroxaban versus vitamin K antagonists: a French nationwide propensity-matched cohort study.
Maura G; Blotière PO; Bouillon K; Billionnet C; Ricordeau P; Alla F; Zureik M
Circulation; 2015 Sep; 132(13):1252-60. PubMed ID: 26199338
[TBL] [Abstract][Full Text] [Related]
19. Outcomes of temporary interruption of rivaroxaban compared with warfarin in patients with nonvalvular atrial fibrillation: results from the rivaroxaban once daily, oral, direct factor Xa inhibition compared with vitamin K antagonism for prevention of stroke and embolism trial in atrial fibrillation (ROCKET AF).
Sherwood MW; Douketis JD; Patel MR; Piccini JP; Hellkamp AS; Lokhnygina Y; Spyropoulos AC; Hankey GJ; Singer DE; Nessel CC; Mahaffey KW; Fox KA; Califf RM; Becker RC;
Circulation; 2014 May; 129(18):1850-9. PubMed ID: 24552831
[TBL] [Abstract][Full Text] [Related]
20. Uninterrupted administration of edoxaban vs vitamin K antagonists in patients undergoing atrial fibrillation catheter ablation: Rationale and design of the ELIMINATE-AF study.
Hohnloser SH; Camm J; Cappato R; Diener HC; Heidbuchel H; Lanz HJ; Mont L; Morillo CA; Smolnik R; Yin OQP; Kautzner J
Clin Cardiol; 2018 Apr; 41(4):440-449. PubMed ID: 29663464
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
